Lexicon Pharmaceuticals Inc (LXRX) (Q3 2026) Earnings Call Highlights: Sonata HCM Data and ...
Lexicon Pharmaceuticals Inc (LXRX) ended Q3 2026 with $183.2 million in cash as it advances pivotal sotagliflozin programs and reports promising preclinical obesity data for pilavapidin. Related Stocks: LXRX ,